GALECTIN THERAPEUTICS INC (GALT) Form 10-Q — May 15, 2026
Galectin Therapeutics reported a net loss of $5.0 million for the first quarter of 2026, driven by $2.2 million in R&D and $1.8 million in G&A expenses. The company holds $14.1 million in cash and has $10 million available under a related-party credit facility, providing a liquidity runway through May 2027. The filing discloses a material weakness in internal controls over financial reporting, specifically regarding the valuation of derivative liabilities associated with contingent interest on convertible notes.
Key figures
- Revenue
- 0
- Cash Position
- 14111000
- Ga Expense
- 1846000
- Rd Expense
- 2231000
- Cash Burn Qo Q
- 3609000
- Available Credit
- 10000000
- Interest Expense
- 1988000
- Shares Outstanding
- 65856898
Price after filing
Close on the filing date to close N calendar days later (from $2.35). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.